Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyclosporine, Eltrombopag or Hetrombopag, and Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia/ Severe Aplastic Anemia

NCT07523009 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07523009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyclosporine, Eltrombopag or Hetrombopag, and Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia/ Severe Aplastic Anemia
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2026
Completion date
December 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

severe aplastic anemia (saa), transfusion-dependent non-severe aplastic anemia